473 related articles for article (PubMed ID: 32500585)
1. Nonavalent human papillomavirus vaccination as alternative treatment for genital warts.
Bossart S; Gabutti MP; Seyed Jafari SM; Hunger RE
Dermatol Ther; 2020 Jul; 33(4):e13771. PubMed ID: 32500585
[TBL] [Abstract][Full Text] [Related]
2. The Clinical and Economic Impact of a Nonavalent Versus Bivalent Human Papillomavirus National Vaccination Program in Taiwan.
Chou HH; Chang SC; Sukarom I; Saxena K; Pavelyev A; Wu YH; Chang CJ
Value Health Reg Issues; 2022 Nov; 32():79-87. PubMed ID: 36116338
[TBL] [Abstract][Full Text] [Related]
3. Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases.
Diakite I; Nguyen S; Sabale U; Pavelyev A; Saxena K; Tajik AA; Wang W; Palmer C
J Med Econ; 2023; 26(1):1085-1098. PubMed ID: 37608730
[TBL] [Abstract][Full Text] [Related]
4. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts.
McCormack PL
Drugs; 2014 Jul; 74(11):1253-83. PubMed ID: 25022951
[TBL] [Abstract][Full Text] [Related]
5. Three cases of recalcitrant cutaneous warts treated with quadrivalent human papillomavirus (HPV) vaccine: the HPV type may not determine the outcome.
Hayashi A; Matsumoto K; Mitsuishi T
Br J Dermatol; 2020 May; 182(5):1285-1287. PubMed ID: 31675436
[No Abstract] [Full Text] [Related]
6. Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain.
Navarro-Illana E; López-Lacort M; Navarro-Illana P; Vilata JJ; Diez-Domingo J
Vaccine; 2017 Jun; 35(25):3342-3346. PubMed ID: 28499554
[TBL] [Abstract][Full Text] [Related]
7. [HPV vaccination with quadrivalent or nonavalent vaccine: an opportunity to eliminate genital warts as well].
van Bergen JEAM
Ned Tijdschr Geneeskd; 2020 Jan; 164():. PubMed ID: 32073799
[TBL] [Abstract][Full Text] [Related]
8. Utility of the Human Papillomavirus Vaccination in Management of HPV-associated Cutaneous Lesions.
Gay J; Johnson N; Kavuru V; Phillips M
Skin Therapy Lett; 2021 Mar; 26(2):6-8. PubMed ID: 33769773
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus.
Broomall EM; Reynolds SM; Jacobson RM
Postgrad Med; 2010 Mar; 122(2):121-9. PubMed ID: 20203463
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus and genital cancer.
Rapose A
Indian J Dermatol Venereol Leprol; 2009; 75(3):236-43; quiz 243-4. PubMed ID: 19439875
[TBL] [Abstract][Full Text] [Related]
11. Updates on human papillomavirus and genital warts and counseling messages from the 2010 Sexually Transmitted Diseases Treatment Guidelines.
Dunne EF; Friedman A; Datta SD; Markowitz LE; Workowski KA
Clin Infect Dis; 2011 Dec; 53 Suppl 3():S143-52. PubMed ID: 22080267
[TBL] [Abstract][Full Text] [Related]
12. Prevention strategies against the human papillomavirus: the effectiveness of vaccination.
Stanley M
Gynecol Oncol; 2007 Nov; 107(2 Suppl 1):S19-23. PubMed ID: 17938013
[TBL] [Abstract][Full Text] [Related]
13. [HPV vaccination and the prevention of genital warts and precancerous lesions-current evidence and evaluation].
Osmani V; Klug SJ
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2021 May; 64(5):590-599. PubMed ID: 33851224
[TBL] [Abstract][Full Text] [Related]
14. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
McCormack PL; Joura EA
BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
[TBL] [Abstract][Full Text] [Related]
15. Time-trend of hospitalizations for anogenital warts in Veneto region in the HPV vaccination era: a cross sectional study (2007-2018).
Cocchio S; Prandi GM; Furlan P; Bertoncello C; Fonzo M; Saia M; Baldovin T; Baldo V
BMC Infect Dis; 2020 Nov; 20(1):857. PubMed ID: 33208109
[TBL] [Abstract][Full Text] [Related]
16. Harnessing the power of prevention: human papillomavirus vaccines.
Mayeaux EJ
Curr Opin Obstet Gynecol; 2006 Feb; 18 Suppl 1():s15-21. PubMed ID: 16520680
[TBL] [Abstract][Full Text] [Related]
17. Vaccines against human papillomavirus infections: protection against cancer, genital warts or both?
Joura EA; Pils S
Clin Microbiol Infect; 2016 Dec; 22 Suppl 5():S125-S127. PubMed ID: 28034371
[TBL] [Abstract][Full Text] [Related]
18. Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine.
Petry KU; Bollaerts K; Bonanni P; Stanley M; Drury R; Joura E; Kjaer SK; Meijer CJLM; Riethmuller D; Soubeyrand B; Van Damme P; Bosch X
Hum Vaccin Immunother; 2018 Jul; 14(7):1800-1806. PubMed ID: 29553886
[TBL] [Abstract][Full Text] [Related]
19. Changes in the Prevalence of Human Papillomavirus Genotypes in Genital Warts Since the Introduction of Prophylactic Vaccines.
Magdaleno-Tapial J; Hernández-Bel P; Ortiz-Salvador JM; Casanova-Esquembre A; Lorca-Spröhnle J; Labrandero-Hoyos C; Peñuelas-Leal R; Sánchez-Carazo JL; Pérez-Ferriols A
Actas Dermosifiliogr; 2022 Oct; 113(9):874-880. PubMed ID: 35688211
[TBL] [Abstract][Full Text] [Related]
20. HPV vaccine promotion: does referring to both cervical cancer and genital warts affect intended and actual vaccination behavior?
Juraskova I; Bari RA; O'Brien MT; McCaffery KJ
Womens Health Issues; 2011; 21(1):71-9. PubMed ID: 21185992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
